The European Medicines Agency committee said the benefits of the new drug, Kisunla, did not outweigh the risks, and it recommended refusing marketing authorization for it.
New study examines association between statin use and the risk of hepatocellular carcinoma and hepatic decompensation in adults with chronic liver disease.
